is a promising gut microbiota for the treatment of type 2 diabetes mellitus (T2DM). stimulates intestinal wall integrity, is an anti-inflammatory agent, and reduces endoplasmic reticulum stress, lipogenesis and gluconeogenesis. These properties make a potential treatment option for T2DM by reducing insulin resistance and increasing insulin sensitivity and glucose tolerance in different tissues. This article explores the possible role of in T2DM management, along with the various methods known to modulate .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242659 | PMC |
| http://dx.doi.org/10.15605/jafes.037.01.13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of clinical benefits and economic value of weight loss in a Swedish population using a simulation model.
Obesity (Silver Spring)
March 2025
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Objective: The objective of this study was to estimate the 10-year clinical benefits and economic value of weight loss in a Swedish population with obesity using a value of weight-loss simulation model.
Methods: Data on the prevalence of and costs associated with obesity and obesity-related complications (ORCs) were applied within an adapted simulation model to evaluate weight-loss benefits for a 2023 Swedish population over 10 years. The 10-year incidence of 10 ORCs and treatment costs in a random cohort of 10,000 individuals were estimated for a stable weight scenario and four weight-loss (5%-20%) scenarios.
Investigation of the Effect of Empagliflozin on Cardiac Sympathetic and Parasympathetic Nerve Activity Analyzed From Heart Rate Variability Frequency in Japanese Patients With Type 2 Diabetes - Results From the EMPYREAN Study.
Circ J
March 2025
Department of Cardiovascular Medicine, Shinshu University School of Medicine.
Background: The EMPA-REG OUTCOME trial confirmed empagliflozin reduced mortality and heart failure hospitalization risk. These findings raised the possibility that empagliflozin may modulate cardiac autonomic function in patients with type 2 diabetes (T2D).
Methods And Results: The EMPYREAN study was a prospective randomized open-label assessor-blinded multicenter investigation of patients with T2D without prior antidiabetic therapy with sodium-glucose cotransporter 2 or dipeptidyl peptidase 4 inhibitors.
The influence of hypertensive disorders of pregnancy on the development of long-term postpartum type 2 diabetes mellitus.
Endocr J
March 2025
Department of Obstetrics and Gynecology, Ehime University Graduate School of Medicine, Ehime 791-0295, Japan.
The association between hypertensive disorders of pregnancy (HDP) and the subsequent development of type 2 diabetes (T2D) in Japanese general population remains unclear. To investigate the influence of HDP on long-term postpartum development of metabolic disorders and T2D, we conducted a population-based cross-sectional study using the 75 g oral glucose tolerance test (75g-OGTT) in 978 parous Japanese women (median age: 66 years). We further evaluated the combined effect of HDP and T2D susceptibility genes on developing T2D.
View Article and Find Full Text PDFUsefulness of an Intermittently Scanned Continuous Glucose Monitoring System for Risk Management of Individuals without Diabetes in Japan.
Biol Pharm Bull
March 2025
Department of Pharmacy, College of Pharmacy, Kinjo Gakuin University, 2-1723 Omori, Moriyama-ku, Nagoya 463-8521, Japan.
We examined whether the glucose levels and awareness of individuals without diabetes changed after using a sensor-based intermittently scanned continuous glucose monitoring (isCGM) system in their daily lives. Japanese individuals without a diabetes diagnosis wore the isCGM system while maintaining a normal lifestyle during the baseline period. A certified diabetes educator coached them on how to improve their lifestyle based on information from sensor data, food journals, and body composition.
View Article and Find Full Text PDFLDL cholesterol levels and treatment intensity in secondary prevention of patients with ischemic heart disease in the primary care setting: a real-world data registry study.
BJGP Open
March 2025
Consorci d'Atenció Primària de Salut Barcelona Esquerra (CAPSBE), Barcelona, Spain
Background: Monitoring LDL cholesterol (LDL-C) and prescribing appropriate treatment is crucial for secondary prevention in primary care.
Aim: We studied LDL-C levels and treatments for ischemic heart disease patients according to target recommendations and assessed factors influencing prescribed drug intensity.
Design & Setting: We examined electronic health records of patients with ischemic heart disease from three primary care centers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!